Proprietary peptide technology platform to develop oral targeted therapy-based drugs that work by blocking biological pathways currently targeted by marketed injectable antibody drugs, and injectables for rare diseases. PTG-300, injectable hepcidin mimetic in Ph 2 Beta-Thalassemia study with initial results expected 2H19. PTG-200, partnered w Janssen, oral GI-restricted IL-23R antagonist for Crohn’s disease completed Ph 1 in November 2018. PN-943, oral GI-restricted alpha4beta7 integrin-specific antagonist in UC in Ph 1, with topline results expected 1H19.
Phase l or ll
Anti-inflammatory, Gastrointestinal, Hematology, Rare Disease
100MM - 500MM
521 Cottonwood Drive
Milpitas, CA 95035
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by